Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences
08 September 2017 - 7:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, will present at key
September investor healthcare conferences. The Company also has
appointed Lindsey Trickett as Vice President of Investor Relations.
Upcoming Conferences:
Tuesday, September 12, 2017Rodman &
Renshaw 19th Annual Global Investment Conference Who:
Nessan Bermingham, Ph.D., President, Chief Executive Officer and
FounderLocation: New York, New YorkPresentation Time: 2:35 pm
EDT
Tuesday, September 26, 2017Cantor
Fitzgerald 3rd Annual Healthcare ConferenceWho: Tom
Barnes, Ph.D., Senior Vice President, Innovative Sciences &
eXtelliaLocation: New York, New YorkPresentation Time: 9:10 am
EDT
Wednesday, September 27, 2017Leerink
Partners Roundtable Series: Rare Disease &
Immuno-Oncology Who: Nessan Bermingham, Ph.D., President,
Chief Executive Officer and FounderLocation: New York, New
YorkPresentation Time: 11:00 am EDT
A live webcast of Intellia’s presentations will be accessible
through the Events and Presentations page of the Investor Relations
section of the company’s website at www.intelliatx.com. To access
the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any
software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each
conference.
Lindsey Trickett joins Intellia as Vice President, Investor
Relations, and will be responsible for leading and overseeing all
aspects of Investor Relations activities. Lindsey brings to
Intellia more than 12 years of biopharmaceutical experience in
varying roles of increasing responsibility at AstraZeneca and
Medimmune, including Treasury, Capital Management and Operations
Strategy. Most recently Lindsey was a Director of Investor
Relations at AstraZeneca for the North American investor base
focusing on immuno-oncology and cardiovascular and metabolic
diseases. Lindsey earned a degree in International Economics at the
University of Kentucky in Lexington and her Masters of Business
Administration with a focus in Finance from Georgetown University
in Washington, D.C.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Intellia Contacts:
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Oct 2023 to Oct 2024